We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.

Delisted

ITCI was delisted on the 1st of April, 2025.

74 hedge funds and large institutions have $405M invested in Intra-Cellular Therapies Inc. in 2015 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 3

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

88% more capital invested

Capital invested by funds: $215M → $405M (+$189M)

57% more funds holding

Funds holding: 4774 (+27)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
74
Holders Change
+27
Holders Change %
+57.45%
% of All Funds
1.97%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
30
Increased
24
Reduced
11
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
NCMW
76
Northern Capital Management (Wisconsin)
Wisconsin
-$215K -12,175 Closed
BRWA
77
B. Riley Wealth Advisors
Florida
-$44 -2,500 Closed

ITCI Hedge Fund Activity: Q1 2015 in Review

74 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2015, worth a combined $405M — up 88% from $215M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ITCI positions and 3 closed out — a net gain of 27 holders — while 24 added to existing stakes and 11 trimmed.

The largest buyer was Wasatch Advisors, opening a new position worth an estimated $22.4M. The largest seller was Redmile Group, cutting an estimated $7.22M.

  • 74 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2015, up from 47 in Q4 2014.
  • Funds reported $405M of Intra-Cellular Therapies Inc. stock for Q1 2015, up 88% quarter-over-quarter.
  • 30 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2015 and 3 closed out, a net change of +27 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2015 was Wasatch Advisors, an estimated $22.4M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2015 was Redmile Group, an estimated $7.22M sold.

Based on aggregated 13F filings for Q1 2015.